These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36765603)

  • 1. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
    Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Imaging Biomarkers for
    Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
    J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma Tumor Dose Response After
    Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
    Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
    J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma.
    Pianka KT; Barahman M; Minocha J; Redmond JW; Schnickel GT; Rose SC; Fowler KJ; Berman ZT
    Eur J Nucl Med Mol Imaging; 2024 Jun; ():. PubMed ID: 38913189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: Application to treatment response.
    Potrebko PS; Shridhar R; Biagioli MC; Sensakovic WF; Andl G; Poleszczuk J; Fox TH
    J Appl Clin Med Phys; 2018 Sep; 19(5):435-443. PubMed ID: 29962026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective SPECT/CT dosimetry following transarterial radioembolization.
    Thompson BC; Dezarn WA
    J Appl Clin Med Phys; 2021 Apr; 22(4):143-150. PubMed ID: 33710776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres.
    Coskun N; Kartal MO; Kartal AS; Cayhan V; Ozdemir M; Canyigit M; Ozdemir E
    Ann Nucl Med; 2024 Jul; 38(7):525-533. PubMed ID: 38647875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioembolization of hepatocarcinoma with
    Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates.
    Brosch J; Gosewisch A; Kaiser L; Seidensticker M; Ricke J; Zellmer J; Bartenstein P; Ziegler S; Ilhan H; Todica A; Böning G
    Phys Med; 2020 Dec; 80():317-326. PubMed ID: 33248338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High quality imaging and dosimetry for yttrium-90 (
    Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of results after 112 radioembolizations with
    Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization (90)Y PET.
    Srinivas SM; Natarajan N; Kuroiwa J; Gallagher S; Nasr E; Shah SN; DiFilippo FP; Obuchowski N; Bazerbashi B; Yu N; McLennan G
    Front Oncol; 2014; 4():255. PubMed ID: 25353006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.